Clinical Trials Logo

Clinical Trial Summary

This is a phase II trial of combination therapy of pembrolizumab and lenvatinib in patients with locally advanced or metastatic cervical cancer that had failed first line of therapy. The hypothesis is the combination of lenvatinib and pembrolizumab will overcome vascular endothelial growth factor (VEGF)-mediated immunosuppression to enhance the response of patients with locally advanced or metastatic cervical cancer.

Clinical Trial Description

The primary endpoint of this phase II study is to determine the objective response rate (partial response [PR] + complete response [CR]) of specific pembrolizumab-lenvatinib combination therapy in patients with locally advanced or metastatic cervical cancer. The phase II portion of the trial will follow Simon's minimax two-stage design1. In the Stage 1, 11 patients will be accrued. If 1 or fewer patients among these 11 patients achieve an objective response with the pembrolizumab-lenvatinib combination therapy, the combination therapy will be rejected and the trial stopped. However, if there are 2 or more patients who exhibit response in the Stage 1, then an additional 24 patients will be entered into the Stage 2, for a total of 35 patients in this phase II study. If 9 or more patients exhibit response among these 35 patients, then the treatment will be considered for further investigation. Any unplanned interim analysis will utilize the sequential conditional probability ratio test (SCPRT)2, which allows an early assessment of statistical evidence for both efficacy and futility, and provides a discordance probability that early trend could be reversed should the trial continue to enroll all 35 patients. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT04865887
Study type Interventional
Source Georgetown University
Status Not yet recruiting
Phase Phase 2
Start date July 2021
Completion date July 2023

See also
  Status Clinical Trial Phase
Recruiting NCT03367871 - Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer Phase 2
Active, not recruiting NCT04537156 - Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) Phase 3
Recruiting NCT03668639 - Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin Phase 2/Phase 3
Not yet recruiting NCT04806945 - A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin/Cisplatin and Paclitaxel) in Patients With Advanced Cervical Cancer Phase 3
Recruiting NCT04185389 - Long-Term Follow-Up of HPV FOCAL Participants
Recruiting NCT03676959 - A Clinical Study of PD-L1 Antibody ZKAB001(Drug Code) in Recurrent or Metastatic Cervical Cancer Phase 1
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Recruiting NCT03876860 - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis N/A
Active, not recruiting NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT00543543 - Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Phase 3
Recruiting NCT04864782 - QL1604 Plus Chemotherapy Versus Chemotherapy in Subjects With Stage ⅣB, Recurrent, or Metastatic Cervical Cancer Phase 2/Phase 3
Recruiting NCT04226313 - Self-sampling for Non-attenders to Cervical Cancer Screening N/A
Active, not recruiting NCT02420665 - Use of High-Resolution Microendoscopy (HRME) in Patients With Cervical Dysplasia Early Phase 1
Suspended NCT02574442 - Pilot Study In Vivo Confocal Microscopy Probe for Cervical Precancer
Not yet recruiting NCT03386695 - Acceptability and Validity of Self Sampling for High Risk HPV Detection Among Women in Maharashtra N/A
Recruiting NCT03155529 - Three-dimensional Study on the Structural Destruction of Pelvic Anatomy in Cervical Cancer N/A
Completed NCT02945111 - Watching Live VIA/VILI Examinations on a Digital Screen May Reduce Patients' Anxiety N/A
Not yet recruiting NCT02875990 - Characterization of Immunosuppressive Signing of Cervical Cancer N/A
Recruiting NCT02503917 - Gynaecologic Organ Segmentation and Motion Tracking Using Ultrasound N/A